There was a point in time – late 2014, early 2015 – that analysts and investors still held hope that Orexigen Therapeutics Inc.'s Contrave (naltrexone/bupropion)would outperform the disappointments that had come before: Vivus Inc. 's Qsymia (phentermine/topiramate) and Arena Pharmaceuticals Inc.'s Belviq (lorcaserin). That hope has faded.
All three drugs continue to flounder and analysts don't believe there are enough marketing dollars or that enough physician education could
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?